-
Economic evaluation in the National Drug Abuse Treatment Clinical Trials Network: Past, present, and future.
Jalali A, Ryan DA, McCollister KE, Marsch LA, Schackman BR, Murphy SM. Economic evaluation in the National Drug Abuse Treatment Clinical Trials Network: Past, present, and future. Journal of Substance Abuse Treatment 2020;112S:18-27.
-
One size does not fit all: A NIDA CTN inspired model for community engaged cultural adaptation.
Burlew AK, McCuistian C, Lanaway D, Hatch-Maillette MA, Shambley-Ebron D. One size does not fit all: A NIDA CTN inspired model for community engaged cultural adaptation. Journal of Substance Abuse Treatment 2020;112S:28-33
-
Increasing collaboration on substance use disorder research with primary care practices through the National Drug Abuse Treatment Clinical Trials Network.
Baldwin L, Mollis B, Witwer E, Hallday JR, Ludden T, Elder N, Tapp H, Donahue KE, Johnson D, Mottus K, Olson AL, Waddell EN, Dolor RJ. Increasing collaboration on substance use disorder research with primary care practices through the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment 2020;112S:34-40
-
Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems.
Boudreau DM, Lapham G, Johnson EA, Bobb JF, Matthews AG, McCormack J, Liu D, Campbell CI, Rossom RC, Binswanger IA, Yarborough BJ, Arnsten JH, Cunningham CO, Glass JE, Murphy MT, Zare M, Hechter RC, Ahmedani B, Braciszewski JM, Horigian VE, Szapocznik J, Samet JH, Schwartz RP, Bradley KA. Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems. Journal of Substance Abuse Treatment 2020;112S:41-48.
-
Service utilization and chronic condition outcomes among primary care patients with substance use disorders and co-occurring chronic conditions.
Stephens KA, West II, Hallgren KA, Mollis B, Ma K, Donovan DM, Stuvek B, Baldwin L. Service utilization and chronic condition outcomes among primary care patients with substance use disorders and co-occurring chronic conditions. Journal of Substance Abuse Treatment 2020;112S:49-55.
-
Using a health information technology survey to explore the availability of addiction treatment data in the electronic health records: A National Drug Abuse Treatment Clinical Trials Network study.
Wu L, Payne EH, Roseman K, Case A, Nelson C, Lindblad R. Using a health information technology survey to explore the availability of addiction treatment data in the electronic health records: A National Drug Abuse Treatment Clinical Trials Network study. Journal of Substance Abuse Treatment 2020;112S:56-62
-
Identifying and responding to trial implementation challenges during multisite clinical trials.
Greer TL, Walker NR, Rethorst CD, Northrup TF, Warden D, Horigian VE, Silverstein M, Shores-Wilson K, Stotts AL, Trivedi MH. Identifying and responding to trial implementation challenges during multisite clinical trials. Journal of Substance Abuse Treatment 2020;112S:63-72.
-
Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state.
Bogan C, Jennings L, Haynes LF, Barth K, Moreland A, Oros M, Goldsby S, Funcell C, Brady KT. Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state. Journal of Substance Abuse Treatment 2020;112S:73-78.
-
Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations.
Winhusen TJ, Lofwall MR, Jones HE, Wilder C, Lindblad R, Schiff DM, Wexelblatt S, Merhar S, Murphy SM, Greenfield SF, Terplan M, Wachman EM, Kropp F, Theobald J, Lewis M, Matthews AG, Guille C, Silverstein M, Rosa CL. Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations. Contemporary Clinical Trials 2020;93:106014.
-
Validation of Addiction Severity Index (ASI) for assessment of psychiatric comorbidity in multi-site randomized controlled trials.
Susukida R, Mojtabai R, Amin-Esmaeili M. Validation of Addiction Severity Index (ASI) for assessment of psychiatric comorbidity in multi-site randomized controlled trials. Journal of Dual Diagnosis 2020;16(3):312-321.